Bc1-2 protein is a potent anti-apoptotic protein that inhibits a mitochondria-operated pathway of apoptosis in many cells. DNA damaging agents and death receptor ligands can activate this mitochondrial apoptotic mechanism. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been suggested to escape from the inhibitory action of Bc1-2 protein. We show that in human breast tumor MCF-7 cells, TRAIL induced a mitochondrial pathway of apoptosis that involved cytochrome c release from mitochondria and activation of caspase 9. The DNA damaging drug doxorubicin also activated this mitochondria-regulated mechanism of apoptosis, which was inhibited in Bc1-2-overexpressing cells. We also demonstrate that in MCF-7 cells Bc1-2 might confer resistance to TRAIL-induced apoptosis, depending on the expression levels of the anti-apoptotic protein. These results indicate that enhanced expression of Bc1-2 in tumor cells can render these cells less sensitive not only to chemotherapeutic drugs but also to TRAIL. Oncogene (2001) 20, 7128 ± 7133.
Keywords: apoptosis; TRAIL; chemotherapy; mitochondria; Bc1-2 There is substantial evidence for the importance of signals from mitochondria during the eector phase of apoptotic cell death (Kroemer et al., 1997) . The role of mitochondria in death receptor-mediated apoptosis has largely been examined in the case of CD95-mediated apoptosis (Scadi et al., 1998) . Results of several investigations have suggested that death receptors like CD95 can trigger the activation of apical caspase 8 to process pro-apoptotic Bid that in turn translocates to the mitochondria and induces the release of cytochrome c into the cytosol (Liu et al., 1996; Yang et al., 1997) . In the presence of dATP, cytochrome c will form a complex with Apaf-1 and procaspase 9 to cause the activation of caspase 9, leading to activation of caspase 3 and downstream apoptotic events (Li et al., 1997; Srinivasula et al., 1998; Zou et al., 1997) .
TRAIL/APO-2 ligand, a recently discovered member of the tumor necrosis factor (TNF) family, is a type-II transmembrane protein which triggers apoptosis mainly in tumor cells (Ashkenazi and Dixit, 1999) . TRAIL also functions as an apoptosis inducer in activation-induced cell death, immune privilege, T cellmediated cytotoxicity and autoimmunity (Grith et al., 1999; Kayagaki et al., 1999; Martinez-Lorenzo et al., 1998; Phillips et al., 1999; Wang et al., 1999) . TRAIL mRNA is constitutively present in many tissues unlike the restricted expression of CD95L, another pro-apoptotic member of the TNF family (Pitti et al., 1996; Wiley et al., 1995) . TRAIL has four dierent speci®c receptors of which TRAIL-R1 and -R2 are death receptors with cytoplasmic death domains that trigger apoptotic cell death whereas TRAIL-R3 and TRAIL-R4 are decoy receptors which are unable to transduce death signals and could inhibit TRAIL-induced apoptosis (Degli-Esposti et al., 1997a,b; Marsters et al., 1997; Mongkolsapaya et al., 1999; Pan et al., 1997a,b; Schneider et al., 1997; Sheridan et al., 1997; Walczak et al., 1997) . However, progress in understanding TRAIL-induced apoptosis has been rather modest thus far and often contradictory results have been reported (Chaudhary et al., 1997; Marsters et al., 1997; Pan et al., 1997a,b; Schneider et al., 1997; Sheridan et al., 1997; Walczak et al., 1997; Yeh et al., 1998) . More recent data have demonstrated that TRAIL receptors recruit the adapter protein FADD for caspase-8 activation (Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000) . Apical caspase processing is followed by activation of Bid, processing of caspases-9, -3 and -7, cleavage of the nuclear enzyme poly(ADP-ribose)polymerase (PARP) and apoptotic cell death (Grith et al., 1999; MacFarlane et al., 2000; Mariani et al., 1997) . However, the role of the mitochondria-regulated pathway in TRAIL-induced apoptosis remains rather controversial. While some studies have reported that neither Bc1-2 nor Bc1-xL inhibited TRAIL-induced cytochrome c redistribution and apoptosis (Keogh et al., 2000; Walczak et al., 2000) , other results have suggested a role of the mitochondria-dependent pathway of apoptosis in TRAIL-activated apoptosis (Hinz et al., 2000; Shi-Yong et al., 2001; Srinivasula et al., 2000) .
In breast carcinoma tissues, a recent report has indicated that the susceptibility of Bc1-2-negative tumors to a number of drugs is signi®cantly higher than that of Bc1-2-positive tumors (Yang et al., 2000) . As recent observations have pointed out to a possible use of TRAIL as a new anti-tumor agent in human malignancies and Bc1-2 is an important anti-apoptotic protein whose expression could be deregulated in breast tumor cells (Rochaix et al., 1999) , we have determined Bc1-2 expression in three breast carcinoma cell lines (MCF-7, MDA-MB231 and EVSA-T) and analysed sensitivity to TRAIL-induced apoptosis. Results shown in Figure 1 indicate that MCF-7 cells expressed the lowest level of Bc1-2 and were the most sensitive of all three lines to TRAIL, suggesting a relationship between Bc1-2 expression and TRAIL sensitivity. However, we can Figure 1 Sensitivity of breast tumor cell lines expressing dierent levels of Bc1-2 protein to TRAIL-mediated apoptosis. (a) Levels of Bc1-2 protein were analysed by Western blotting in the human breast cancer cell lines MCF-7, MDA-MB231 and EVSA-T, maintained in culture in RPMI 1640 containing 10% FCS, 1 mM L-glutamine and gentamycin, at 378C in a humidi®ed 5% CO 2 /95% air incubator. After detachment with RPMI/ EDTA, cells (4610 5 ) were washed with PBS and lysed in 20 ml Laemmli buer. Samples were sonicated and proteins were resolved on SDS-polyacrylamide minigels and detected as described previously (Ruiz-Ruiz et al., 2000) . Blots were probed with anti-hBc1-2 mAb from DAKO (Denmark). a-Tubulin levels were determined as a control of loaded protein with mouse antitubulin mAb (Sigma). (b) MCF-7, MDA-MB231 and EVSA-T cells were treated for 48 h with the indicated doses of recombinant human TRAIL/Apo2L, which was obtained from PreproTech ECLTD (London, UK). Cell viability was determined by the crystal violet method as described previously (Ruiz-Ruiz et al., 2000) . Results are representative of at least two dierent experiments Figure 2 Overexpression of Bc1-2 protects human breast tumor MCF-7 cells from death induced by TRAIL. Stable cells lines overexpressing human Bc1-2 protein were generated by transfection of MCF-7 cells with either pcDNA3-neo or pcDNA3-neohbc1-2 DNA, using FUGENE reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions. Resistant clones were selected in culture medium with 2 mg/ml G418 sulfate (Sigma Chemical Co.) and maintained as described above. not exclude the possibility that other parameters apart from Bc1-2 expression levels may be underlying these eects since EVSA-T cells were as resistant to TRAIL as MDA-MB231 cells while expressing much lower levels of Bc1-2 (Figure 1 ). To further examine the role of Bc1-2 and mitochondria in TRAIL-induced apoptosis in human breast tumor cells, avoiding the intrinsic variability of experiments using dierent cell lines, we generated breast tumor MCF-7 cells ectopically expressing anti-apoptotic human Bc1-2 protein. We obtained several clones whose levels of Bc1-2 are shown in Figure 2a . All these clones showed similar growth rates (not shown) and three of them expressed very high levels of Bc1-2 (Figure 2a ). In these cells we determined the sensitivity to TRAIL-induced cell death. Figure 2b shows that clones B6, C2 and D5, expressing the highest levels of Bc1-2 protein, were completely resistant to TRAIL-induced cell death. In contrast, clone B5 expressing a lower Bc1-2 protein level, was as sensitive as mock-transfected cells to TRAIL-activated cell loss. To better characterize the TRAIL sensitivity of MCF-7
Bc1-2 clones, we carried out dose-response and time course experiments in the low (B5) and high (B6) Bc1-2 expressing clones, respectively. As shown in Figure 2c , clone B5 was as sensitive to TRAIL as the control (neo) clone in 2 days treatment experiments. In contrast, after incubation for up to 4 days with the highest dose of TRAIL, clone B6 showed only a slight decrease in cell viability (data not shown).
It has been recently reported that TRAIL-induced apoptosis was not inhibited in either Bc1-2 or Bcl-x Lexpressing cells based on the fact that the same cells were resistant to DNA damage-induced apoptosis . Since MCF-7 cells may be either sensitive or resistant to TRAIL depending on the expression level of Bc1-2 (Figure 2) , we compared the apoptosis-inducing capacity of both TRAIL and the DNA-damaging drug doxorubicin in two MCF-7 clones that expressed markedly dierent levels of Bc1-2 protein. Phosphatidylserine (PS) exposure in the outer side of the plasma membrane is an apoptosis marker that can be determined by annexin-V binding. We analysed annexin-V binding in mock-transfected and Bc1-2 cells treated with either TRAIL (Figure 3a) or doxorubicin (Figure 3b) . The results obtained indicated that whereas doxorubicin-induced apoptosis was markedly abrogated in both MCF-7
Bc1-2 clones, treatment with TRAIL caused PS translocation only in clone B5 that expressed a lower level of Bc1-2 protein. The nuclear enzyme PARP is a substrate of executioner Figure 3 Dierential sensitivity of MCF-7
Bc1-2 cells to TRAIL or doxorubicin-induced apoptosis. MCF-7 neo and two dierent clones of MCF-7
Bc1-2 cells were treated for (a) 24 h with TRAIL (250 ng/ml) or (b) 48 h with doxorubicin (500 ng/ml, Sigma, St. Louis, MO, USA). Apoptosis was assessed by measuring PS externalization and PARP cleavage. PS exposure on the surface of apoptotic cells was detected by¯ow cytometry after staining with Anexin-V-FLUOS (Roche Molecular Biochemicals). Flow cytometry was performed on a FACScan cytometer using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA).
Results are representative of at least three independent experiments. In (c) MCF-7 neo and MCF-7 Bc1-2 cells were treated for 8 h with TRAIL (250 ng/ml) or 48 h with doxorubicin (500 ng/ml). Caspase-mediated cleavage of PARP was determined by Western blotting with rabbit polyclonal antiserum against PARP (Roche Molecular Biochemicals, Germany). Arrows show intact PARP and the 85 kDa proteolytic fragment of PARP. Results are representative of at least two independent experiments Bc1-2 blocks TRAIL-induced apoptosis in breast tumor cells C Ruiz de Almodo Â var et al caspases and its cleavage is considered an important event in nuclear apoptosis. Doxorubicin caused PARP cleavage in MCF-7 cells that was prevented in Bc1-2-overexpressing clones B5 and B6 (Figure 3c ). However, TRAIL-induced PARP cleavage was only inhibited in clone B6 (Figure 3c ), the one expressing the highest level of Bc1-2 protein.
Results not shown indicated that condensation of chromatin, another feature of nuclear apoptosis, was also completely inhibited in clone B6 following treatment with TRAIL, as compared to mock-transfected MCF-7 cells. According to recent published data, either Bc1-2 or Bcl-x L fails to block cytochrome c release from mitochondria during TRAIL-induced apoptosis in leukemic cells (Keogh et al., 2000) and TRAILinduced apoptosis depends on activation of both caspase-8 and caspase-3 rather than on the disruption of mitochondrial integrity . In contrast to these results, other data suggested that Bc1-2 and Bcl-x L inhibited TRAILinduced apoptosis (Shi-Yong et al., 2001; Srinivasula et al., 2000) . We have tried to understand these apparently discrepant data by examining the mitochondria-regulated apoptotic pathway in the MCF-7 Bc1-2 clones described above. As shown in Figure   4a , TRAIL-induced release of cytochrome c from mitochondria was not prevented in clone B5, in agreement with the data indicating that TRAILinduced apoptosis was not inhibited in these cells (Figures 2 and 3) . However, cytochrome c release upon doxorubicin treatment was clearly reduced in this clone (Figure 4a ). These results were in agreement with those previously described in leukemic cells (Keogh et al., 2000) and suggested that in contrast to DNA-damaging agents, TRAIL may activate a mitochondria-operated death pathway that is not regulated by Bc1-2. However, as MCF-7 clones expressing higher levels of Bc1-2 than clone B5 were resistant to TRAIL-induced apoptosis (Figures 2 and 3) , we also analysed cytochrome c release in one of these resistant clones. The results obtained demonstrated that in cultures from clone B6, neither doxorubicin nor TRAIL caused the release of cytochrome c into the cytosol of treated cells (Figure 4a ). Altogether these results strongly suggested that in breast tumor MCF-7 cells, TRAIL activated a mitochondria-regulated apoptotic pathway which can be subjected to regulation by Bc1-2, provided that this anti-apoptotic protein is expressed at a suciently high level. MCF-7 neo and MCF-7 Bc1-2 (clones B5 and B6) cells were treated either for 48 h with doxorubicin (500 ng/ml) or for 8 h with TRAIL (250 ng/ml). Following these treatments, cells were lysed and cytosolic fractions were separated from mitochondriacontaining fractions as described previously (Ruiz-Ruiz et al., 2000) . Proteins (40 mg) were mixed with Laemmli buer and resolved on 12% SDS-polyacrylamide minigels. Blots were probed with either mouse anti-cytochrome c mAb (a) or mouse anti-Bax mAb (b), both obtained from Pharmingen (San Diego, CA, USA). Processing of procaspase-9 (c) and loss of procaspase-8 (d) were also analysed by Western blotting in total cell extracts of MCF-7 neo and MCF-7 Bc1-2 clone B6 cells treated for 8 h with 250 ng/ml TRAIL. Rabbit anti-cleaved caspase-9 polyclonal antibody was purchased from New England BioLabs Inc. (Beverly, MA, USA). Mouse antihuman caspase-8 mAb was from Cell Diagnostica (MuÈ nster, Germany). In each case, a-tubulin levels were examined as a control of loaded protein Oncogene Bc1-2 blocks TRAIL-induced apoptosis in breast tumor cells C Ruiz de Almodo Â var et al To further substantiate the above observations, we examined other mitochondria-related apoptotic events such as Bax translocation and activation of caspase-9. Translocation of pro-apoptotic Bax from cytosol to mitochondria is frequently involved in the release of cytochrome c from mitochondria and could be antagonized by Bc1-2 in cells treated with dierent apoptotic stimuli (Gross et al., 1998; Murphy et al., 1999 Murphy et al., , 2000 . Results of Figure 4b demonstrate that in mock-transfected MCF-7 cells, as well as in the low Bc1-2 expressing clone B5, induction of apoptosis by TRAIL was accompanied by the translocation of Bax protein to a mitochondria-containing cellular fraction. Interestingly, this eect of TRAIL was completely prevented in MCF-7
Bc1-2 clone B6 cells, that are markedly resistant to TRAIL-induced cytochrome c release and apoptosis. In contrast, doxorubicin-induced Bax translocation was similarly reduced in both B5 and B6 clones with respect to the control clone (Figure 4b ). However, a certain amount of Bax was still translocated to the mitochondria-containing fraction in clones B5 and B6 treated with doxorubicin, despite the inhibition of phosphatidylserine externalization, PARP cleavage and cytochrome c release observed in these clones (Figures 3 and 4a) . These data were veri®ed by analysing the loss of Bax protein from the cytosol of treated cells (data not shown). These results suggest that a step downstream of Bax translocation should be also inhibited by Bc1-2 to prevent the release of cytochrome c from mitochondria and the subsequent activation of caspases in doxorubicin-treated cells.
Once released from mitochondria, cytochrome c will bind to Apaf-1 in the presence of dATP, an event that triggers oligomerization of Apaf-1/cytochrome c in complexes that activate procaspase-9 (Li et al., 1997; Srinivasula et al., 1998; Zou et al., 1997) . Figure 4c illustrates that TRAIL activated the processing of caspase-9 in MCF-7 cells and this eect was completely inhibited by Bc1-2 overexpression in clone B6.
Anti-apoptotic Bc1-2 inhibits the activation of executioner caspases and apoptosis by preventing the release of cytochrome c from mitochondria (Kluck et al., 1997) . In this study we have shown that the activation by TRAIL of a mitochondria-operated pathway of apoptosis was clearly inhibited in MCF-7 cells over-expressing Bc1-2 (clone B6). To exclude the possibility that the observed inhibition of this pathway in clone B6 was due to defect on the earliest steps of TRAIL-induced apoptosis, e.g. DISC formation (Bodmer et al., 2000) , rather than to the inhibitory eect of Bc1-2 overexpression on cytochrome c release, we examined the processing of apical procaspase-8 following addition of TRAIL to cultures of MCF-7 cells from clone B6. As shown in Figure 4d , we found no dierences between mock transfected and Bc1-2-overexpressing MCF-7 cells (clone B6) in the loss of procaspase-8 upon treatment with TRAIL. In summary our results demonstrate that dierences in the expressed levels of Bc1-2 protein may determine their sensitivity to TRAIL-induced apoptosis and could also explain why previous data have excluded a role of the mitochondria in TRAIL-induced apoptosis in other cell lines (Keogh et al., 2000; Walczak et al., 2000) . Furthermore, as Bc1-2 levels appear to be an important factor in inhibiting apoptosis in human breast carcinomas (Rochaix et al., 1999) , our data suggest that the use of TRAIL in the treatment of these neoplasias may require further development of anti-Bc1-2 strategies to block the function of this protein in the tumor cells.
